Thermo Fisher Scientific Inc. (TMO - Free Report) has been gaining investor confidence on continued positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 23.2% in comparison with the industry’s 9.3% rise and the S&P 500’s 1.7% gain.
This leading scientific instrument maker has a market cap of $96.69 billion. The company has an earnings growth rate of 12.5% for the next three to five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What Makes the Stock an Attractive Pick?
Strength in All End Markets
In third-quarter 2018, Thermo Fisher witnessed strength in all end markets categorized either by customer type or geography. In pharma and biotech, the company saw high-teens growth.
In diagnostics and healthcare, Thermo Fisher delivered mid-single digit growth on broad-based strength across its businesses serving this end market. Globally, Thermo Fisher witnessed strength across all regions along with continued progress in China where the company saw a growth rate of more than 20%.
BD’s Advanced Bioprocessing to Boost Bioproduction Growth
Thermo Fisher recently completed the buyout of Advanced Bioprocessing business from Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD. We believe this acquisition to significantly expand the company’s Life Sciences Solutions line of offerings. We note that Thermo Scientific offers a broad portfolio of purification products supporting biopharmaceutical development within Life Sciences Solutions.
Focus on Emerging Markets
Thermo Fisher boasts strong international operations and has witnessed consistent growth in the Asia-Pacific and emerging markets. The company plans to continue to strengthen its foothold in emerging markets, such as China and India, and to translate this success to other regions such as South Korea, Russia and Brazil. In third-quarter 2018, the standout contributor was China, where the company delivered more than 20% growth rate.
Other Key Picks
Other top-ranked stocks in the broader medical space are Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 currently.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>